Targeted therapy with low-dose chemo for newly diagnosed Ph+ B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial combines a targeted antibody therapy with a low dose of chemotherapy to treat adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combo can help shrink or eliminate the leukemia with fewer side effects than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) that hasn't been treated yet.
- Your leukemia cells must have a specific marker called CD22 on their surface.
- You must be generally well enough to participate, with adequate organ function and a performance status that allows daily activities.
- You must not have leukemia in the brain or spinal cord, or spread to other organs outside the blood and bone marrow.
- You must not have had prior treatment for this leukemia, and you must not have other blood cancers like chronic myeloid leukemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Hear when a new Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.